Abstract
This study investigated the role of a multispecific organic anion transporter, Oatp1a4/Slco1a4, in drug transport across the blood-brain barrier. In vitro transport studies using human embryonic kidney 293 cells expressing mouse Oatp1a4 identified the following compounds as Oatp1a4 substrates: pitavastatin (Km = 8.3 μM), rosuvastatin (Km = 12 μM), pravastatin, taurocholate (Km = 40 μM), digoxin, ochratoxin A, and [d-penicillamine2,5]-enkephalin. Double immunohistochemical staining of Oatp1a4 with P-glycoprotein (P-gp) or glial fibrillary acidic protein demonstrated that Oatp1a4 signals colocalized with P-gp signals partly but not with glial fibrillary acidic protein, suggesting that Oatp1a4 is expressed in both the luminal and the abluminal membranes of mouse brain capillary endothelial cells. The brain-to-blood transport of pitavastatin, rosuvastatin, pravastatin, and taurocholate after microinjection into the cerebral cortex was significantly decreased in Oatp1a4(−/−) mice compared with that in wild-type mice. The blood-to-brain transport of pitavastatin, rosuvastatin, taurocholate, and ochratoxin A, determined by in situ brain perfusion, was significantly lower in Oatp1a4(−/−) mice than in wild-type mice, whereas transport of pravastatin and [d-penicillamine2,5]-enkephalin was unchanged. The blood-to-brain transport of digoxin was significantly lower in Oatp1a4(−/−) mice than in wild-type mice only when P-gp was inhibited by N-(4-[2-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)ethyl]-phenyl)-9,10-dihydro-5-methoxy-9-oxo-4-acridine carboxamide (GF120918). Taken together, these results show that Oatp1a4 can mediate the brain-to-blood and blood-to-brain transport of its substrate drugs across the blood-brain barrier. The brain-to-plasma ratio of taurocholate, pitavastatin, and rosuvastatin was close to the capillary volume in wild-type mice, and it was not affected by Oatp1a4 dysfunction. Whether Oatp1a4 can deliver drugs from the blood to the brain remains controversial.
Footnotes
This work was supported in part by Grant-in-Aid for Scientific Research (A) from the Ministry of Education, Culture, Sports, Science and Technology [Grant 20249008] (to Y.S.); and Grant-in-Aid for Scientific Research (B) from the Ministry of Education, Culture, Sports, Science and Technology [Grant 20390046] (to H.K.).
Article, publication date, and citation information can be found at http://dmd.aspetjournals.org.
doi:10.1124/dmd.109.029454
-
- BBB
- blood-brain barrier
- P-gp
- P-glycoprotein
- Bcrp/BCRP
- breast cancer resistance protein
- Oatp
- organic anion transporter peptide
- BQ-123
- cyclo-d-Trp-d-Asp-Pro-d-Val-Leu
- DPDPE
- [d-penicillamine2,5]-enkephalin
- m
- mouse
- r
- rat
- GF120918
- N-(4-[2-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)ethyl]-phenyl)-9,10-dihydro-5-methoxy-9-oxo-4-acridine carboxamide, Elacridar
- HEK
- human embryonic kidney
- PCR
- polymerase chain reaction
- bp
- base pairs
- GS
- gene specific
- E
- endogenous
- T
- targeted
- Neo
- neomycin cassette-specific
- Oat
- organic anion transporter
- Mdr
- multidrug resistance
- Mrp/MRP
- multidrug resistance-associated protein
- BSA
- bovine serum albumin
- PBS
- phosphate-buffered saline
- TTBS
- Tris-buffered saline containing 0.05% Tween 20
- GFAP
- glial fibrillary acidic protein
- BEI
- brain efflux index
- LC
- liquid chromatography
- MS
- mass spectrometry
- Ro 64-0802
- [3R,4R,5S]-4-acetamido-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylate phosphate.
- Received July 11, 2009.
- Accepted October 13, 2009.
- Copyright © 2010 by The American Society for Pharmacology and Experimental Therapeutics
DMD articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|